1. ������ѧ����ҽԺ, a. ҩ����,b. ѪҺ��, ���� 100044�� 2.������ѧҩѧԺҩ�¹������ٴ�ҩѧϵ,���� 100191
Clinical Observation of Hepatoprotective Agents for Prevention of Liver Injury During Initial Chemotherapy of Patients with Acute Myeloid Leukemia
WANG Wen-hua1a,2, LIU Li-ping1a,2, ZHU Hong-hu1b, GU Jian1a*
1.People��s Hospital of Peking University, a. Department of Pharmacy, b. Department of Hematology, Beijing 100044, China; 2. Department of Pharmacy Administration and Clinical Pharmacy, Peking University Health Science Center, Beijing 100191, China
Abstract��OBJECTIVE To investigate the preventive effect of hepatoprotective agents against liver injury induced by initial chemotherapy in patients with acute myeloid leukemia (AML). METHODS A total of 128 patients with newly diagnosed AML in the department of hematology of one tertiary hospital who received IA regimen were enrolled into this study during the period of January 2012 to December 2015. Using a retrospective study design, differences were assessed between the group treated with hepatoprotective agents (experimental group; n=99) and that withou hepatoprotective agents (control group; n=29). The experimental group was further divided into four groups, ie, glutathione group, magnesium isoglycyrrhizinate group, glutathione combined with magnesium isoglycyrrhizinate group, and the other group. The patients in the experimental group were treated with hepatoprotective agents at the first time of inducing chemotherapy while the patients in the control group received inducing chemotherapy only. The biochemical indexes for liver function of all the patients were recorded. RESULTS There was no significant difference in the incidence of liver injury between the experimental group and control group (P>0.05),and the preventive effects in the three groups were similar (P>0.05). Cox regression analysis of the related factors of the occurrence of liver injury showed that there was no significant difference (P>0.05). CONCLUSION Prophylactic use of hepatoprotective agents does not reduce the incidence of liver injury among treatment-naive patients with AML who have received IA regimen.
���Ļ�������ƽ�����������˽�. ����ҩ�ڼ�����ϵ��Ѫ�����λ����и�����Ԥ�����õ��ٴ��۲�[J]. �й�ҩѧ��־, 2017, 52(1): 72-75.
WANG Wen-hua, LIU Li-ping, ZHU Hong-hu, GU Jian. Clinical Observation of Hepatoprotective Agents for Prevention of Liver Injury During Initial Chemotherapy of Patients with Acute Myeloid Leukemia. Chinese Pharmaceutical Journal, 2017, 52(1): 72-75.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN clinical practice guideline in oncology: acute myeloid leukemia (V.1.2016) . NCCN, 2016 . http:// www. nccn. org/ professionals/ physician _gls/ pdf/ aml. pdf.
[2]
DRUG-INDUCED LIVER DISEASE STUDY GROUP. Guidelines for the management of drug- induced liver injury. Chin J Hepatol (�л����ಡ��־), 2015, 23 (11): 810-820.
[3]
LAN D, GANY Q, WANG L, et al. Study about the effect of preventive use hepatoprotective agents with chemotherapy for breast cancer drug-induced liver injury. J Guangxi Med Univ(����ҽ�ƴ�ѧѧ��), 2015,32(2): 281-283.
[4]
LI Y, LIN Y. 2013 Annual Congress of Chinese Thoracic Society . Dalian:Chinese medical association, 2013:261-262.
[5]
ZENG L L, ZHOU G Q. Diagnostic criteria of drug-induced liver injury and their clinical application. Adverse Drug React J(ҩ�ﲻ����Ӧ��־), 2011, 13 (1): 17-20.
[6]
BRUNO V, GRAZIA A, MARIELLA S C, et al. Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opin Drug Saf, 2016, 15(9):1219-1238.
[7]
PETRONIJEVIC M, ILIC K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBaseTM . J Clin Pharmacol, 2013, 53(4): 435-443.
[8]
ZHOU Y, YANG L, LIAO Z, et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21 789 patients . Eur J Gastroenterol Hepatol, 2013, 25(7): 825-829.
[9]
MANDELLI F, VIGNETTI M, SUCIU S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10 . J Clin Oncol, 2009, 27(32): 5397-5403. SUN Y J, QI W X, YAO Y. Prevention and treatment of glutathione in chemotherapy-induced liver injury . Bull Chin Cancer (�й�����), 2015, 24(1): 57-63. JIN W Y, YU F. Progress in the pharmacological and clinical researches of magnesium isoglycyrrhizinate in prevention and treatment of drug-induced liver injury . Prog Pharm Sci(ҩѧ��չ), 2013, 37(4): 161-166. YUE Z L, FU R, RUAN E B, et al. The incidence and risk factors of chemotherapy-induced liver disease of the patients with acute non-lymphocytic leukemia . Chin Pract Intern Med(�й�ʵ���ڿ���־), 2009, 29(11): 1009-1011. GU S W, ZHAO B. Magnesium isoglycyrrhizinate caused liver damage: case report. Chin J Liver Dis, Electron Version (�й����ಡ��־���Ӱ�), 2012, 4(3): 24-25.
2017, Vol. 52 
